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A B S T R A C T
Background: Multiple sclerosis is a disorder related to demyelination of axons. Iron is an essential cofactor in
myelin synthesis. Previously, we described two children (males of mixed ancestry) with relapsing-remitting
multiple sclerosis (RRMS) where long-term remission was achieved by regular iron supplementation. A genetic
defect in iron metabolism was postulated, suggesting that more advanced genetic studies could shed new light on
disease pathophysiology related to iron.
Methods: Whole exome sequencing (WES) was performed to identify causal pathways. Blood tests were per-
formed over a 10 year period to monitor the long-term effect of a supplementation regimen. Clinical wellbeing
was assessed quarterly by a pediatric neurologist and regular feedback was obtained from the schoolteachers.
Results: WES revealed gene variants involved in iron absorption and transport, in the transmembrane protease,
serine 6 (TMPRSS6) and transferrin (TF) genes; multiple genetic variants in CUBN, which encodes cubilin (a
receptor involved in the absorption of vitamin B12 as well as the reabsorption of transferrin-bound iron and
vitamin D in the kidneys); SLC25A37 (involved in iron transport into mitochondria) and CD163 (a scavenger
receptor involved in hemorrhage resolution). Variants were also found in COQ3, involved with synthesis of
Coenzyme Q10 in mitochondria. Neither of the children had the HLA-DRB1*1501 allele associated with in-
creased genetic risk for MS, suggesting that the genetic contribution of iron-related genetic variants may be
instrumental in childhood MS. In both children the RRMS has remained stable without activity over the last
10 years since initiation of nutritional supplementation and maintenance of normal iron levels, confirming the
role of iron deficiency in disease pathogenesis in these patients.
Conclusion: Our findings highlight the potential value of WES to identify heritable risk factors that could affect
the reabsorption of transferrin-bound iron in the kidneys causing sustained iron loss, together with inhibition of
vitamin B12 absorption and vitamin D reabsorption (CUBN) and iron transport into mitochondria (SLC25A37) as
the sole site of heme synthesis. This supports a model for RRMS in children with an apparent iron-deficient
biochemical subtype of MS, with oligodendrocyte cell death and impaired myelination possibly caused by
deficits of energy- and antioxidant capacity in mitochondria.
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Multiple sclerosis (MS) is the most common cause of disability in
young adults due to inflammatory demyelination of nerve axons. In
approximately 3–5% of cases the diagnosis is made before the age of 18,
referred to as pediatric MS. Consensus definitions for the diagnosis of
pediatric MS and related disorders were proposed in 2007 by the
International Pediatric Multiple Sclerosis Study Group (IPMSSG), and
revised in 2012 to include components of the 2010 revision of the
McDonald criteria [1]. Pediatric MS is defined by two or more de-
myelinating events separated in time and space. The criteria would be
satisfied by new magnetic resonance imaging (MRI) lesions that appear
three months or longer after the first clinical event together with clin-
ical symptoms consistent with central nervous system (CNS) demyeli-
naton and after exclusion of differential diagnoses [2].
In MS, wide differences in age at diagnosis and disability may be
indicative of subgroups of patients subject to different genetic and en-
vironmental influences [3,4]. Therefore, elucidating a common etiology
to enable optimal treatment for disability prevention has been elusive
[5]. An effective disease modifying therapy (DMT) for progressive MS
has not been identified, and the results of clinical trials in pediatric MS
to date have been generally disappointing and not without severe side-
effects [6]. The notion of “this is the best treatment available – there are
no other options” should never be accepted blindly. A translational
model, pathology supported genetic testing (PSGT) [7], provides the
necessary tools to evaluate clues presented by “black swan” cases that
could shed new light on the etiology of MS. “Black swans” are un-
expected, improbable events that challenge existing scientific theories,
but in retrospect contribute to the elucidation of complex problems (the
sighting of one black swan nullifies the theory that all swans are white)
[8]. A case in point is the association of low iron status described in two
children with relapsing-remitting MS (RRMS) [2]. Iron supplementa-
tion normalized the iron parameters and improved MS symptoms, but
as soon as the supplementation was stopped, serum iron levels fell
dramatically [2].
Low blood iron levels are generally attributed to lower iron ab-
sorption, since the current textbook view of iron retention by the body
dismisses the notion that iron is lost through the kidneys, stating that
less than 0.1% of body iron is lost daily, mostly as a result of desqua-
mation and blood loss [9]. This view is so entrenched that validated
tests for urinary iron are not available in pathology laboratories. The
iron deficiency experienced by the two children was therefore hy-
pothesized to involve genetic defects in iron absorption or iron meta-
bolism, such as iron retention in macrophages as a result of chronic
inflammation [10].
Inflammation is regarded to be the primary disease mechanism
impacting both demyelination and neurodegeneration in MS [7,10]. MS
is characterized by the presence of inflammatory demyelinating lesions
and brain volume loss of approximately 0.7% per year compared to a
loss of 0.1% to 0.3% in normal aging [11]. The association of MS with
inflammation is corroborated by the fact that most genetic variations
related to MS risk are found within immune system-related genes. The
genetic marker with the largest effect size lies within the human leu-
kocyte antigen (HLA) complex: the risk for a diagnosis of MS increases
about three times in the presence of HLA-DRB1*1501. However, several
studies have found that this allele does not predict disease severity or
brain atrophy in MS [12–15]. Other non-HLA susceptibility genes with
small individual effects implicated in MS risk by genome-wide asso-
ciation studies (GWAS) have also not shown associations with disease
severity [16,17]. The finding that the HLA DRB1*1501 allele is not
detected in all patients with MS while some people never develop MS
despite inheritance of this allele, supports the suggestion of distinct
subtypes involving other genes and/or environmental triggers. Sup-
pression of inflammation by anti-inflammatory treatment has not been
able to stop or reverse brain atrophy or disability progression [11,18],
suggesting that multiple disease mechanisms are involved.
Currently, the most widely accepted theory of MS etiology (and the
reason for DMTs) is that MS is an autoimmune disease, involving the
migration of immune cells from the blood into the CNS where they
attack normal myelin, after being activated by a myelin-related antigen
[19]. However, the absence of a circulating diagnostic antigen/anti-
body argues against this hypothesis [20,21]. A thorough histopathology
study by Prineas and Parratt (2018) using indirect immuno-
fluorescence, found no evidence for a diagnostic circulating anti-myelin or
anti-oligodendrocyte autoantibody [22]. This critical finding may hope-
fully redefine the concept of autoimmunity in the etiology of MS. These
authors concluded that a more appropriate theory should include the
phagocytosis of oligodendrocytes (the cells that produce myelin) and
dysfunctional myelin by activated microglia and monocyte-derived
macrophages, secondary to the death of the oligodendrocytes.
It is therefore imperative to elucidate the cause(s) of oligoden-
drocyte death leading to demyelination, so that hypotheses may be
formulated for the mitigation of such insults. Six risk factors for de-
myelination and disability in MS have been identified, involving defi-
ciencies or metabolic dysfunction of biochemical pathways and me-
chanisms: (1) Oxidative damage to lipids, DNA and mitochondria in
oligodendrocytes and neurons [23]; (2) Vitamin D deficiency [24–27];
(3) S-adenosyl methionine (SAMe) deficiency caused by deficits in fo-
late-vitamin B12 metabolism [28–30]; (4) Copper deficiency (cuprizone
mouse model of MS) [31]; (5) Hypoxia [32–34] and, notably, (6) Iron
dysregulation [7].
Both iron overload and iron deficiency have been investigated in MS
[35,36], reviewed in [7]. The two children evaluated in the present
study who had severe iron deficiency, developed tumefactive demye-
lination (very large areas of demyelination) [2]. A recent multi-centre
dietary study found that children with MS had a significantly lower
intake of iron from their diet than children without MS, but with no
differences in the other nutrients investigated [37]. Herbert et al.
(2018) found that iron deficiency affected myelin parameters on MRI:
Low blood iron status in females with MS was associated with lower
fractional anisotropy (a measure of white matter microstructure) and
worse disability, compared to females with higher iron parameters
[38]. Notably, vitamin D deficiency, associated with both MS risk [24]
and disability progression [25], is also associated with decreased iron
levels and anemia in children with inflammatory bowel disease due to
increased hepcidin levels [39]. Vitamin D reduces the circulating
concentration of hepcidin, a protein that inhibits iron absorption by the
enterocytes in the gut [40].
The six risk factors mentioned above, especially iron deficiency,
may all lead to oligodendrocyte cell death and demyelination due to
their effects on energy production in mitochondria. It has previously
been shown that oligodendrocytes have a particularly large energy re-
quirement for myelin synthesis [41]. It is of interest that iron, copper,
SAMe and oxygen are directly involved in the electron transport chain
(ETC): Iron is a cofactor of Complexes I–IV [42], copper is involved in
electron transport in Complex IV [43], while two enzymes (COQ3 and
COQ5) use SAMe as cofactor to methylate coenzyme Q (CoQ) [44]. The
ultimate electron acceptor in the ETC is oxygen. Defective oxygen de-
livery to mitochondria (hypoxia) can be caused by vascular pathology
leading to hypoperfusion [32–34], or by environmental toxins such as
cigarette smoke that contains molecules such as cyanide, carbon mon-
oxide and nitric oxide [45]. These toxins block the reduction site be-
tween iron and copper in Complex IV that should be occupied by
oxygen [43]. It is evident that deficiencies (or defective metabolism) of
any of the structural or active components of the ETC could cause in-
hibition of energy production in oligodendrocytes that could lead to
their demise. Deficiencies could result from low dietary intake [37,46],
and/or genetic variations that inhibit absorption or transport of these
components in the blood or into mitochondria, or cause their enhanced
excretion from the body.
The objectives of the present study were first to employ whole
exome sequencing (WES) to investigate possible genetic causes for the
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iron deficiency experienced by the two pediatric RRMS cases described
by Van Toorn et al. [2]. Variations in known iron deficiency-related
genes listed by Constantine et al. (2008) were included in the in-
vestigation [47]. Second, we describe the clinical wellbeing of the
children, including scholastic progress and participation in extramural
activities after a period of 10 years, during which time they followed a
restorative program that included metabolic components to counteract
the nutritional deficiencies and oxidative stress listed above [48].
2. Patients and methods
2.1. Subjects
The subjects were two pediatric RRMS cases previously described
[2], who demonstrated severe recurrent iron deficiency when iron
supplementation was discontinued. Variations in iron-related genes in
the children were investigated. The clinical wellbeing of the children
was monitored, including scholastic progress and participation in ex-
tramural activities over a period of 10 years.
2.2. Ethical clearance
Ethics Approval for the study was granted by the Human Research
Ethics Committee (HREC) of Stellenbosch University under reference
number N07/09/203. The parents provided written informed consent
that their children may participate in the study and for publication of
the results. All procedures performed were in accordance with the
ethical standards of the institutional research committee and with the
1964 Helsinki declaration and its later amendments.
2.3. Clinical investigations
Serial MRI with associated clinical findings of the two children were
described in 2010 [2]. The children (both males of mixed ancestry who
were referred to as Case 1 and Case 2) were followed up every
4–6months at the Tygerberg Children's Hospital, Cape Town, South
Africa. Iron parameters performed at the National Health Laboratory
Service, Tygerberg Hospital, Cape Town, were recorded every
4–6months as described previously [2]. Both children described in the
present study were exposed to second-hand smoke from their parents at
the time of their diagnosis with MS.
2.4. Personalized nutritional supplementation
Both children presented with sustained iron deficiency and were
prescribed iron supplementation (4mg/kg/day). Since their iron levels
dropped when the supplementation was stopped, they have continued
to take iron supplements. In addition, considering the six risk-related
metabolic pathways for disability referred to in the Introduction, the
children followed a restorative supplementation program that con-
tained essential nutrients considered beneficial for myelin production
and maintenance [2,48].
2.5. Genetic studies
Whole exome sequencing (WES) was performed at the Central
Analytical Facility (Stellenbosch University, Stellenbosch, South Africa)
using the Ion ProtonTM sequencing system (Thermo Fisher Scientific,
Waltham, MA, USA) according to the method previously described by
Van der Merwe et al. (2017) [49]. The Ion AmpliSeq™ Exome RDY kit
(Thermo Fisher Scientific, Waltham, MA, USA) was used to amplify the
whole exome and subsequent library construction. Samples were se-
quenced with the One Touch workflow on an Ion P1™ Chip v3 using Hi
Q™ Sequencing chemistry. Variant calling was performed on the Tor-
rentServer against an ethnically concordant major allele reference
genome based on Genome Reference Consortium Human Build 37 patch
release 13 (GRCh37.p13), NCBI Homo sapiens Annotation Release 105
[50]. Variants were annotated in IonReporter 5.6 and prioritised based
on their role in iron deficiency [47,51], by using an in-house pipeline of
clinically relevant genes selected from the approximately 20,000
human genes. All variants reported were verified by Sanger sequencing.
Taqman analysis, using haplotype tagging by rs9271366, was employed
to investigate the presence of the HLA-DRB1*1501 allele associated
with increased risk for MS [52].
3. Results
3.1. Genetic investigations including whole exome sequencing
Using the method outlined above, variant calling using a high
stringency setting, identified a total of 24,916 variants for Case 1, and
26,550 variants for Case 2. When the variants were annotated in
IonReporter and prioritised with our pipeline based on their role in iron
deficiency, several genetic variants were identified in metabolic path-
ways that may be associated with the MS disease process as outlined in
the Introduction. Variants in iron metabolism were identified in both
children that may have resulted in their iron deficiency, including
pathways of absorption, transfer and excretion of iron (Table 1). The
discovery of CUBN variants could relate to deficiencies or dysfunction
of vitamin B12 and vitamin D as well. Genetic variants were also
identified in the metabolic pathways of iron transport into mitochon-
dria (SLC25A37) and of CoQ synthesis.
3.2. Clinical findings
Iron supplementation was initiated in both RRMS children following
a third relapse. Case 1 first became symptomatic at 3 years 8months of
age and subsequently experienced relapses at 4 years 4months and
5 years 1months of age. The age of onset in case 2 was 5 years with
relapses occurring at 5 years 8months and 11 years 8months. In both
cases, serial MRI confirmed dissemination in space (DIS) and dis-
semination in time (DIT) [2].
Regular 4–6 monthly review by a pediatric neurologist revealed no
further symptoms or signs suggestive of neurological relapse for
11 years (case 1) and 9 years (case 2). Repeat MRI was only performed
when clinically indicated. Case 2 had repeat MRI studies at 12 years
3months and 14 years 9months of age due to epileptic seizures. The
seizures were related to healed scar tissue from previous demyelination
events and no active lesions were identified. Case 1 never warranted
further neuroimaging studies.
3.3. Scholastic performance
Both children required remedial scholastic support due to the pre-
vious demyelinating episodes. Hearing, vision and motor ability ap-
peared unaffected. Case 1 is currently coping in mainstream schooling
with an interest in subjects such as computer applications for tech-
nology, business studies and art. He partakes in soccer, and excels in
athletics, competing at a Provincial level against main-stream athletes
in his age group.
Formal cognitive evaluation in Case 2 revealed mild intellectual
disability with epilepsy. He attended a school for children with special
needs until 18 years of age where he underwent training in beading and
embroidery and took part in athletics. At present he lives with his
mother and does care work.
4. Discussion
The present study was undertaken to ascertain whether genetic in-
formation from WES could shed light on the clinical profile of two
children diagnosed with MS, including large areas of demyelination and
a sustained decrease of serum iron parameters when supplementation
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was discontinued [2]. The presence of genetic variants may have con-
tributed to the diagnosis of RRMS in the two children, which was made
according to clinical criteria presented by the consensus definitions of
the IPMSSG [1,2]. The identification of the variants may provide insight
into the impact of deficits in the biochemical pathways of the six risk
factors for demyelination and disability mentioned in the Introduction.
Addressing the deficits in these metabolic pathways led to clinical im-
provement as described above. Genetic variations in key pathways that
could have impaired iron absorption in the children are shown in
Table 1.
4.1. Iron absorption: TMPRSS6
TMPRSS6 has previously been shown to be associated with iron
deficiency [53–55]. Case 1 is heterozygous for rs855791 and
rs2543519, while Case 2 is homozygous for rs2543519 (Table 1). We
have also demonstrated that homozygosity for the TT allele of rs855791
was associated with significantly lower blood iron parameters com-
pared to wild-type CC in 107 South African MS patients [66]. Delbini
et al. (2010) [53] found that rs2543519 was significantly associated
with iron-refractory anemia; however in our study, Child 1 who is
heterozygous for rs2543519, and Child 2 who is homozygous for this
variant, both responded to sustained oral iron supplementation [2].
4.2. Iron transport: TF
Two genetic variations in the children were also detection in the TF
gene, which encodes the main iron transport protein in the blood,
transferrin. Case 1 is heterozygous for rs1130459 and rs1880669, while
Case 2 is homozygous for both variants (Table 1). Many TF variants
have previously been associated with decreased iron concentrations
[56,57]. Constantine et al. [47] found an association of rs1880669 with
iron parameters [58].
4.3. Iron loss: CUBN
Notably, WES revealed that both children have several genetic
variants in CUBN, the gene that codes for cubilin, a 460 kDa receptor
that binds to several ligands including the intrinsic factor (IF)-vitamin
B12 complex, apolipoprotein A1, high density lipoprotein (HDL) and
albumin [61]. Kozyraki et al. [59] discovered that a cubilin-megalin
complex is involved in the reuptake of iron-bound transferrin in the
kidney [59]. Furthermore, cubilin facilitates the reabsorption of vi-
tamin D in the kidney where it is activated [60]. Cubilin lacks a
transmembrane domain, and functions in concert with megalin and
amnionless, which mediate endocytosis of cubilin-bound ligands [61].
Enhanced excretion of the ligands can be demonstrated in the urine
when the function of any one of these three receptor proteins is com-
promised [61]. High-penetrance CUBN mutations such as 3916C→T
and IVS-intraCUB6 C→G cause juvenile hereditary megaloblastic an-
emia 1 (MGA1, OMIM 261100; Imerslund-Gräsbeck syndrome), a rare
autosomal recessive disorder characterized by an inability to absorb
vitamin B12 in the terminal portion of the ileum and neurological
symptoms [67]. Several functional polymorphisms in CUBN have un-
known effects on megaloblastic anemia [67]. Neither of the two chil-
dren in our study had symptoms of megaloblastic anemia; therefore the
CUBN variants detected in the children are not clinically relevant for
megaloblastic anemia. Case 1 is heterozygous for 3 variants, while Case
2 is heterozygous for 4 variants (Table 1).
4.4. Iron import into mitochondria: SLC25A37
Both children were heterozygous for SLC25A37 rs3736032. This
gene encodes mitoferrin-1, which functions as an essential iron im-
porter for the synthesis of mitochondrial heme and iron‑sulfur clusters
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rs3736032 AA genotype is extremely rare with a frequency of less than
0.1 in all natural population groups [68], compatible with a severe
impact on mortality. Considering that the two children already have an
iron deficiency, impaired import of iron into their mitochondria may
have an important impact on energy production and myelination.
4.4.1. Iron deficiency in Mitochondria: impact on energy production and
oxidation – significance for MS
The significance of the genetic variations detected for the two
children with MS, related to iron loss through the kidneys (CUBN) and
decreased iron import into mitochondria (SLC25A37) becomes clear in
light of the discovery by Yoon et al. [42]: In cultivated cells, iron
chelation by desferroxamine mesylate (DFO) caused down-regulation of
the iron-protein subunit (SDHB) of Complex II of the ETC, resulting in a
collapse of mitochondrial membrane potential, a significant decrease of
intracellular ATP (53.8%) and irreversible growth arrest of the cells.
The reduced expression of SDHB was due to an IRE in the 5′ un-
translated region of the mRNA, causing sensitivity to iron depletion. In
addition, two AUUUA sequences on the 3’-UTR mRNA-destabilizing
elements of the mRNA caused an even faster decrease of the mRNA
level [42]. A similar downregulation of dehydrogenase activity as a
result of iron depletion was found by Ackrell et al. (1985) in rat skeletal
muscle mitochondria: both Complexes I and II showed 70% less activity
[69]. The authors concluded that that iron-deficient complexes were
either not assembled or were lost after assembly. A study by Dutta et al.
[70] demonstrated a reduction in the activities of respiratory chain
complexes I (61%) and III (40%) in mitochondrial preparations from
the motor cortex in postmortem tissue from MS patients, leading to a
mismatch between energy demand and reduced synthesis of ATP. Since
Complexes I and II synthesise CoQH2, a powerful antioxidant in mi-
tochondria [71], iron deficiency could paradoxically increase the oxi-
dation level in mitochondria, contrary to the general perception that
high iron, not low iron, causes oxidation. Lassmann and van Horssen
(2016) describe the deleterious effects of mitochondrial oxidation in
MS, including decreased ATP levels, oligodendrocyte apoptosis, de-
myelination, neurodegeneration and progressive disability [23]. No-
tably, high daily intake of fruits and vegetables in South African MS
patients was significantly associated with improved disability scores
[72] as measured by the Expanded Disability Status Scale (EDSS) [73].
This may possibly be related to their antioxidant content that would
ameliorate the oxidative process.
4.5. Hemorrhage resolution: CD163
The oxidative process may furthermore have been enhanced in the
two children by missense genetic variations in CD163 (Table 1) which
encodes a 130-kDa member of the scavenger receptor cysteine-rich
(SRCR) superfamily [64,65]. CD163 (also known as macrophage sti-
mulating-1 receptor, MST1R) is a scavenger receptor exclusively ex-
pressed in monocytes, macrophages and microglia in response to he-
moglobin released from ruptured erythrocytes. During hemorrhage
resolution, free hemoglobin is bound by haptoglobin, and hemoglobin/
haptoglobin complexes are endocytosed by the CD163 macrophage
receptors, enabling iron clearance and storage in ferritin, thereby pro-
tecting tissues from oxidative damage [64,65]. Evidence has been found
of damage to cerebral veins and perivascular iron deposition due to
hemorrhage, to be more common in MS than control brain samples
[74,75]. Haptoglobin is expressed by oligodendrocytes following in-
tracerebral hemorrhage [76]. Although it is not known whether genetic
variations in CD163 impair the function of CD163/MST1R, MST1R
expression is significantly downregulated in brain material from MS
patients compared with controls [77]. Impaired hemorrhage resolution
by CD163 may enhance inflammation and decrease termination of the
immune response, leading to an overactivation of the immune system
[78]. Soluble CD163 (sCD163) measured in serum has been examined
as a biomarker in MS [79], while their study also confirmed the
presence of human endogenous retrovirus (HERV-W) envelope epitopes
on non-classical monocytes from patients with MS. It has previously
been suggested that viral infections such as Epstein-Barr and sub-
sequent activation of HERV-W, also known as the MS-associated ret-
roviral element (MSRV), may be involved in the inflammatory demise
of oligodendrocytes [80].
4.6. Biosynthesis of coenzyme Q: COQ3
Genetic variations were also found in COQ3 (Table 1), which en-
codes an O-methylase that forms part of a complex that synthesises CoQ
in mitochondria [44]. The importance of genetic variations in COQ3 for
MS is that CoQ is a powerful antioxidant in mitochondria [71], but it
can only function as such if it has two methoxy groups, which are added
by COQ3 [44]. The two methoxy groups of CoQ are involved in the firm
hydrogen bonding that takes place in the binding pockets of complexes
I, II and III during electron transfer [81]. Methyl groups added to CoQ
by the enzymes COQ3 and COQ5 are derived from SAMe, which is
transported into mitochondria [82]. While genetic variations in COQ3
have not been related to primary CoQ10 deficiency in humans [83],
homozygous mutations in C. elegans coq3 that lack methyltransferase
activity displayed delayed development and lethality at the embryonic
stage in the next generation [84].
4.7. Significance for MS of the genetic variations detected in this study
Neither of the children had rs9271366 which tags the HLA
DRB1*1501 allele associated with increased risk for MS, raising the
possibility that the genetic contributions of the other gene variants
identified in the context of the 6 disease risk pathways mentioned in the
Introduction were instrumental in MS pathogenesis due to cumulative
risk. These variants, especially CUBN, need to be investigated in a
larger cohort of MS patients, together with biochemical determinations
and measurements of renal exretion of iron, vitamin B12 and vitamin D.
The possible roles of the other cubilin ligands such as HDL and
Apolipoprotein A in MS should also be investigated.
The genetic variations found in the two children, although not
identical, were present in the same disease pathways, and strongly
suggest that WES could be implemented to identify impediments in the
metabolic pathways involved in energy production in oligodendrocytes,
causing reduced synthesis of myelin by oligodendrocytes, leading to
their apoptosis and subsequent inflammation due to the scavenging
functions of microglia [85]. Mitochondrial dysfunction may be parti-
cularly deleterious in demyelinated axons that have an increased en-
ergy demand [23]. Although the results of translational studies take
long to become established in clinical practice, the finding of iron-de-
ficient diets in children with MS compared to controls [37] could en-
hance the visibility of iron deficiency in MS. This finding provides
support for the first description of iron deficiency in a subgroup of MS
patients [86], paving the way for the current investigation. Considering
the uncertain benefits of current anti-inflammatory treatment for chil-
dren with MS, sustained nutritional intervention that supports mi-
tochondrial function, myelin production and remyelination of axons
seems reasonable [2,48]. This approach was successful in limiting dis-
ability progression in the two children with MS. During the follow-up
period, the children did not relapse again and showed no MS-related
neurological deficits, suggesting that deficiencies of these nutrients
were involved in the pathogenesis.
4.8. Limitations of the study
The primary limitation of the present study is that urinary iron was
not measured in the children, since the possibility of iron loss through
the kidneys was not considered until the discovery of the CUBN variants
in the children. Although the functional significance of all the variants
in Table 1 were not demonstrated by in vitro studies, clinical relevance
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for iron metabolism has been reported for TMPRSS6 rs855791 [53–55]
and TF rs1880669 [56–58] (Table 1).
4.9. Strength of the study
The strength of the study lies in the continued measurements of
serum iron parameters in the children [2] that revealed a dramatic
decrease in iron parameters following termination of iron supple-
mentation. The detection of the CUBN variants is a novel finding that
opens a new avenue for future research. It may therefore be advisable to
include iron measurements in the recently proposed Pediatric MS Tool-
Kit, that includes three risk factors: environmental tobacco smoke ex-
posure, sun exposure and vitamin D intake [87].
5. Conclusion
WES provided evidence of genetic variations that could explain the
sustained iron deficiency in the two cases of pediatric MS. The dis-
covery of CUBN variants could relate to deficiencies of vitamin B12 and
vitamin D as well. MS symptoms in both children were alleviated fol-
lowing supplementation with these nutrients together with anti-
oxidants. Although some damage was sustained, supplementation re-
sulted in an absence of relapses and restoration of function over
10 years, suggesting the following course of events in their MS etiology:
1. A combination of genetic and environmental factors causing a lack
of substrates essential for ATP synthesis (e.g. iron) led to oxidative
stress in mitochondria, apoptosis of oligodendrocytes and sub-
sequent demyelination. Scavenging phagocytes caused further oxi-
dative damage to lipids, proteins and DNA in oligodendrocytes and
the demyelinated neurons. Exposure of the children to tobacco
smoke from their parents could have exacerbated reactive oxygen
species (ROS) generation.
2. Genetic variations in inflammatory pathways, such as ineffective
scavenging of hemoglobin deposits at the blood-brain barrier, could
have led to subsequent over-activation of the immune system and
delayed termination of the inflammatory process.
3. Nutritional supplementation provided alleviation of oxidative stress
and maintenance of adequate remyelination.
Further studies should investigate whether this model would be
applicable to other children diagnosed with MS.
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